Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Synmosa Biopharma Corporation (4114:TWSE), powered by AI.
Synmosa Biopharma Corporation is currently trading at $29.05. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Synmosa Biopharma Corporation on Alpha Lenz.
View Synmosa Biopharma Corporation's valuation metrics on Alpha Lenz.
“Synmosa Biopharma Corporation's ROE is 10.3%. Explore profitability and growth together.”
Ask for details →Synmosa Biopharma Corporation is a specialty pharmaceutical company headquartered in Taiwan, recognized for its comprehensive involvement in the healthcare sector. The company specializes in the research, development, manufacturing, and distribution of a wide array of pharmaceutical products, including prescription medicines, over-the-counter drugs, active pharmaceutical ingredients, medical devices, cosmetics, and chemical food additives. It plays a pivotal role in areas such as cardiovascular, respiratory, sex hormones, urology, and oncology therapies, providing essential solutions for both acute and chronic conditions. Synmosa also manufactures and markets environmental drugs and health-related products, supporting both human and animal health. Its product portfolio is built on advanced technology platforms including effervescent tablets, nasal sprays, metered dose inhalers, hormones, and granules, underlining its innovative capacity in drug delivery and formulation. With five GMP-certified manufacturing facilities and a strong footprint not only in Taiwan but also across markets in Asia, the Middle East, Africa, and Latin America, Synmosa Biopharma Corporation stands as one of the leading forces driving pharmaceutical standards and healthcare advancement in the region.
“Synmosa Biopharma Corporation's ROE is 10.3%. Explore profitability and growth together.”
Ask for details →Synmosa Biopharma Corporation (ticker: 4114) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
The current price is 29.05 with a P/E ratio of -x and P/B of -x.
ROE is 10.29% and operating margin is 12.57%. Annual revenue is $6.2B.